AI Article Synopsis
- Atopic dermatitis (AD) is a chronic skin condition that often begins in childhood and can lead to other health issues, with dupilumab being the first biologic treatment approved for moderate to severe cases in adults and adolescents.
- A study reviewed the off-label use of dupilumab in children, showing that 89.5% of patients accessed the medication after about 9 weeks, with varying dosing guidelines based on age.
- The findings indicated that children generally tolerated dupilumab well, but optimal dosing for those under 12 years is still unclear, and the study faced limitations in data collection due to its retrospective nature.
Article Abstract
Background: Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease, typically starting in infancy, with increased risk for subsequent extracutaneous atopic morbidities. Dupilumab is the first biologic agent targeting type 2 inflammation approved by the U.S. Food and Drug Administration (USFDA); it was licensed in 2017 for adults with moderate to severe AD and 2 years later for adolescents. Systemic treatment for pediatric AD remains a significant unmet medical need.
Objective: To analyze off-label use of dupilumab in children with AD.
Methods: Multicenter retrospective review that evaluated children who were prescribed dupilumab for moderate to severe AD.
Results: One hundred eleven of 124 patients (89.5%) gained access to dupilumab after a mean of 9 weeks. The dosing range was 4 to 15.5 mg/kg for the loading dose and 2.0 to 15.3 mg/kg every other week for maintenance. The range was widest for 6- to 11-year-olds and was related to use of either full or half of adult dosing. Associated morbidities, treatment response, and adverse events were comparable to those in previous adolescent and adult trials.
Limitations: The retrospective design of the study limited uniform data collection.
Conclusion: Access to dupilumab was achievable for the majority of children after a mean 9-week delay because of insurance payment denial. This review supports dupilumab response and tolerability in children. Optimal dosing for patients younger than 12 years has not been defined. Availability of the drug in 2 different concentrations is an important safety issue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2019.10.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Off-Label Use of Monoclonal Antibodies for Eosinophilic Esophagitis in Humans: A Scoping Review.
Biomedicines
November 2024
Department of Pharmacy, Peking Union Medical College Hospital, 1 Shuaifuyuan Wangfujing, Beijing 100730, China.
: Eosinophilic esophagitis (EoE) is a rare, chronic immune-mediated disorder with limited treatment options. Despite the U.S.
View Article and Find Full Text PDFThe off-label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab-induced erythrodermic psoriasiform dermatitis. A modified, spaced dupilumab dosing regimen, combined with cyclosporine, successfully managed both conditions, offering a promising strategy for managing dupilumab adverse effects while maintaining control over chronic actinic dermatitis.
View Article and Find Full Text PDFBiological drugs for the treatment of children with chronic spontaneous urticaria.
Expert Rev Clin Immunol
December 2024
Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Introduction: There is a significant prevalence of chronic spontaneous urticaria (CSU) in children across the globe. Some children with CSU do not achieve disease control with first-line antihistamine treatment and may need anti-IgE therapy with omalizumab. Recently, several novel treatment options, including dupilumab and BTK inhibitors, showed promising results in the treatment of antihistamine-refractory CSU in adults.
View Article and Find Full Text PDFDupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control.
J Clin Immunol
November 2024
Department of Pediatrics, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Lindwurmstraße 4 , Munich, European Union (EU), D-80337 , Germany.
Purpose: Netherton syndrome (NS) is a rare inborn error of immunity (IEI) with an incidence of approximately 1:200,000 and the phenotypic triad of trichorrhexis invaginate (bamboo hair), congenital ichthyosiform erythroderma, and multiple atopic manifestations. Treatment options especially in infants are scarce and generally not licensed.
Methods: Case report of a 9-week-old infant with NS treated with dupilumab off-label.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!